Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Azelio in connection with its rights issue (1)
Mandate

Vinge has advised Azelio in connection with its rights issue

October 26, 2022 Capital Markets and Public M&A

Vinge has advised Azelio AB (publ) on a fully guaranteed rights issue, which will provide Azelio with issue proceeds amounting to approximately SEK 300 million before deduction of transaction costs.

The new shares and warrants issued by reason of the rights issue are expected to be admitted to trading on Nasdaq First North Growth Market on 31 October 2022.

Azelio is a public Swedish company, specializing in in energy storage with electricity and heat production. Azelio’s system (“TES.POD “) for renewable, Stirling-based electricity production and heat production is based on continuous technological development and refinement. The technology makes the energy dispatchable, enabling renewable energy to be made available around-the-clock.

Azelio’s shares are listed on Nasdaq First North Growth Market.

Vinge’s team consisted primarily of David Andersson, William Kåge, Joel Magnusson, Benjamin Vafaeian and Joacim Malmqvist.

 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025